YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Australian shares are experiencing a positive trend, with recent gains driven by a rebound in technology stocks. In this context, the term "penny stock" may seem outdated, yet it continues to highlight opportunities within smaller or less-…
* Halvio Capital generated a return of 5.62% during Q4 2025, outperforming major equity benchmarks compared to the returns of 2.2% and 2.7% for the Russell 1000 Growth Index and S&P 500, respectively, for the same period. * The portfolio e…
The Australian market is poised for a quiet end to the week, with futures indicating a slight decline of around 0.5%, following a turbulent period influenced by high job cuts in the US and ongoing concerns about AI valuations. Despite thes…
The Australian market is navigating a period of volatility following the Federal Reserve's decision to cut interest rates in the U.S., with local shares trending downward and futures for the ASX 200 suggesting a slight loss at open. Despit…
ADELAIDE, Australia, Dec. 29, 2023 (GLOBE NEWSWIRE) -- Mayne Pharma Group Limited (ASX: MYX) today announced that Shawn Patrick O’Brien, Chief Executive Officer of Mayne Pharma, will present at the 42nd Annual J.P. Morgan Healthcare Confer…
Key Insights Mayne Pharma Group's significant retail investors ownership suggests that the key decisions are influenced by shareholders from the larger public A total of 23 investors have a majority stake in the company with 50% ownership…
Even if it's not a huge purchase, we think it was good to see that Shawn O’Brien, the CEO, MD & Director of Mayne Pharma Group Limited (ASX:MYX) recently shelled out AU$141k to buy stock, at AU$3.80 per share. Nevertheless, it only increas…
This week we saw the Mayne Pharma Group Limited (ASX:MYX) share price climb by 10%. But spare a thought for the long term holders, who have held the stock as it bled value over the last five years. Five years have seen the share price desc…
Novan stockholders "will not receive any payment" from deals worth millions of dollars to sell the bankrupt company's assets. Continue reading
Mayne Pharma Group (ASX:MYX) Full Year 2023 Results Key Financial Results Revenue: AU$183.6m (down 57% from FY 2022). Net loss: AU$317.4m (loss widened by 21% from FY 2022). AU$3.86 loss per share (further deteriorated from AU$3.20 loss in…
Key Insights Significant control over Mayne Pharma Group by retail investors implies that the general public has more power to influence management and governance-related decisions 50% of the business is held by the top 25 shareholders Ins…
Mayne Pharma Group Limited (ASX:MYX) shareholders should be happy to see the share price up 27% in the last quarter. But will that heal all the wounds inflicted over 5 years of declines? Unlikely. Five years have seen the share price desce…
Mayne Pharma Group Limited's (ASX:MYX) price-to-sales (or "P/S") ratio of 0.9x might make it look like a strong buy right now compared to the Pharmaceuticals industry in Australia, where around half of the companies have P/S ratios above 8…
Even if it's not a huge purchase, we think it was good to see that Frank Condella, the Independent Non-Executive Chairman of Mayne Pharma Group Limited (ASX:MYX) recently shelled out AU$74k to buy stock, at AU$3.52 per share. While that is…
Key Insights Mayne Pharma Group's estimated fair value is AU$7.77 based on 2 Stage Free Cash Flow to Equity Mayne Pharma Group is estimated to be 49% undervalued based on current share price of AU$3.94 Our fair value estimate is 35% lower…
Dr. Reddy's Laboratories Ltd (NYSE: RDY) has agreed to acquire the U.S. generic prescription product portfolio of Australia-based Mayne Pharma Group Limited (OTC: MAYND) (OTC: MAYNF) (OTC: MYPHY). Under the terms of the agreement, Dr. Redd…
Every investor in Mayne Pharma Group Limited (ASX:MYX) should be aware of the most powerful shareholder groups. We can see that individual investors own the lion's share in the company with 56% ownership. In other words, the group stands t…
The latest analyst coverage could presage a bad day for Mayne Pharma Group Limited (ASX:MYX), with the analysts making across-the-board cuts to their statutory estimates that might leave shareholders a little shell-shocked. This report foc…
We think intelligent long term investing is the way to go. But no-one is immune from buying too high. For example, after five long years the Mayne Pharma Group Limited (ASX:MYX) share price is a whole 54% lower. That's an unpleasant experi…
One thing we could say about the analysts on Mayne Pharma Group Limited (ASX:MYX) - they aren't optimistic, having just made a major negative revision to their near-term (statutory) forecasts for the organization. Both revenue and earnings…
How far off is Mayne Pharma Group Limited (ASX:MYX) from its intrinsic value? Using the most recent financial data, we'll take a look at whether the stock is fairly priced by taking the expected future cash flows and discounting them to th…
Catalent Inc (NYSE: CTLT) agreed to acquire Metrics Contract Services, a full-service specialty Contract Development and Manufacturing Organization, for $475 million from Mayne Pharma Group Limited. Upon completion, the acquisition will st…
ADELAIDE, Australia, Aug. 2, 2022 /PRNewswire/ -- Mayne Pharma Group Limited (ASX: MYX) and Mithra Pharmaceuticals, SA (Euronext Brussels: MITRA) are pleased to announce NEXTSTELLIS® (drospirenone and estetrol tablets) has been nominated f…
Mayne Pharma enters into strategic agreement with GoodRx GoodRx and Mayne Pharma to collaborate and deliver an enhanced NEXTSTELLIS® direct-to-consumer (DTC) program ADELAIDE, Australia, July 29, 2022 /PRNewswire/ -- Mayne Pharma Group Lim…
A look at the shareholders of Mayne Pharma Group Limited (ASX:MYX) can tell us which group is most powerful. Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit of smaller comp…
It is doubtless a positive to see that the Mayne Pharma Group Limited (ASX:MYX) share price has gained some 36% in the last three months. But spare a thought for the long term holders, who have held the stock as it bled value over the last…
Insiders were net buyers of Mayne Pharma Group Limited's (ASX:MYX ) stock during the past year. That is, insiders bought more stock than they sold. Although we don't think shareholders should simply follow insider transactions, logic dicta…
Market forces rained on the parade of Mayne Pharma Group Limited (ASX:MYX) shareholders today, when the analysts downgraded their forecasts for this year. Both revenue and earnings per share (EPS) estimates were cut sharply as the analysts…
The big shareholder groups in Mayne Pharma Group Limited (ASX:MYX) have power over the company. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. I generally lik…
We're definitely into long term investing, but some companies are simply bad investments over any time frame. We don't wish catastrophic capital loss on anyone. For example, we sympathize with anyone who was caught holding Mayne Pharma Gro…
ADELAIDE, Australia, Nov. 30, 2021 /PRNewswire/ -- Mayne Pharma Group Limited (ASX: MYX) and Mithra Pharmaceuticals, SA (Euronext Brussels: MITRA) are very pleased to announce the Therapeutic Goods Administration (TGA) has approved the nov…
We feel now is a pretty good time to analyse Mayne Pharma Group Limited's (ASX:MYX) business as it appears the company may be on the cusp of a considerable accomplishment. Mayne Pharma Group Limited, a specialty pharmaceutical company, man…
RALEIGH, N.C., Sept. 21, 2021 /PRNewswire/ -- Mayne Pharma is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved LEXETTE® (halobetasol propionate) foam, 0.05% for use in adolescents. LEXETTE, a super potent t…
Potential Mayne Pharma Group Limited (ASX:MYX) shareholders may wish to note that the Independent Non-Executive Director, Frank Condella, recently bought AU$137k worth of stock, paying AU$0.33 for each share. We reckon that's a good sign,…
Long term investing works well, but it doesn't always work for each individual stock. It hits us in the gut when we see fellow investors suffer a loss. Anyone who held Mayne Pharma Group Limited (ASX:MYX) for five years would be nursing th…
Long term investing works well, but it doesn't always work for each individual stock. It hits us in the gut when we see fellow investors suffer a loss. Anyone who held Mayne Pharma Group Limited (ASX:MYX) for five years would be nursing th…